GlassScriptPhysician profile
John Christopher Karpie
NPI 1972705408
$6,274.88
in general payments reported to CMS, 2019-2025
29 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,445 · 2020: $127 · 2021: $454 · 2022: $391 · 2023: $359 · 2024: $328 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prodigy Surgical Distribution, INC. | $1,847.35 | 2019-2022 | |
| Arthrex, INC. | $1,334.00 | 2019 | |
| Depuy Synthes Sales INC. | $1,022.30 | 2019-2024 | Monovisc, Orthovisc |
| Smith+Nephew, INC. | $483.20 | 2019-2025 | Healicoil, Journey II, Legion |
| Ferring Pharmaceuticals INC. | $300.67 | 2019-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $238.38 | 2019-2021 | |
| Amgen INC. | $174.93 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Abbott Laboratories | $116.29 | 2019-2025 | Proclaim |
| Horizon Therapeutics Plc | $89.54 | 2019-2023 | Krystexxa |
| Pacira Pharmaceuticals Incorporated | $70.51 | 2019-2023 | Zilretta, Exparel, Iovera |
| Medical Device Business Services, INC. | $68.28 | 2019 | |
| Innovation Technologies INC | $58.80 | 2022 | |
| Heraeus Medical, LLC. | $49.35 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $43.04 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Bioventus LLC | $42.93 | 2022-2024 | Exogen Ultrasound Bone Healing System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.23 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $34.28 | 2025 | |
| Misonix INC | $31.93 | 2021 | |
| Vericel Corporation | $28.41 | 2023 | Maci |
| Avanos Medical | $27.65 | 2021-2023 | Grpro 2.1 |
| Anika Therapeutics, INC. | $22.73 | 2021 | |
| Fidia Pharma USA INC. | $21.59 | 2022 | |
| Orthofix Medical, INC. | $20.23 | 2021 | |
| Ibsa Pharma INC. | $19.69 | 2024 | Licart, Tirosint |
| Kci USA, INC. | $19.49 | 2022 | |
| Silk Road Medical, INC. | $18.98 | 2020 | |
| Pfizer INC. | $17.99 | 2020 | |
| Djo, LLC | $16.31 | 2022 | |
| Arthrosurface Incorporated | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Karpie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.